Clinical Trial Update: Medicus’ Phase 2 Study of D-MNA in Nodular BCC Now More Than 50% Enrolled
Medicus Pharma Ltd.’s phase 2 clinical study (SKNJCT-003) has now randomized more than 50% of the 60 patients expected to be enrolled in the study of D-MNA in nodular basal cell carcinoma. D-MNA is noninvasive treatment consisting of a micro-array of needles containing doxorubicin. The study is currently underway in nine clinical sites in United […]